PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

With the bull market starting its fourth year, and yields on U.S. debt falling to the lowest levels since early this year, ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

India faces a silent anaemia epidemic, with rising cases across all demographics. In most cases, public tend to disregard its ...

Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry’s ...